linjc16/ctgov huggingface dataset:
Evaluation of University Students' Knowledge Levels and Perceptions of the Physiotherapist

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the knowledge, perceptions and perspectives of students about physiotherapy and rehabilitation profession, who are studying in different departments, especially in the health sector in Turkey.

Official Title
-----------------
Evaluation of University Students' Knowledge Levels and Perceptions of the Physiotherapist in Turkey: A Health-Areas University Example

Conditions
-----------------
Physical Therapist

Intervention / Treatment
-----------------
* Other: College student


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals between the ages of 18-25 who are students and continue their education at Acibadem Mehmet Ali Aydinlar University Exclusion Criteria: Students in the physiotherapy and rehabilitation department Students with serious mental illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Students<br> | Other: College student<br>* Our research will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students studying in departments other than Physiotherapy and Rehabilitation at Acibadem Mehmet Ali Aydinlar University.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge of students about the physiotherapist profession | 5-point Likert (5=Strongly Agree, 0=Strongly Disagree) given to open-ended questions. As the score increases, the level of knowledge good [the minimum (18 point) and maximum values (90 point)], higher scores were mean a better outcome. | Baseline time | 
| Perceptions of students about the physiotherapist profession | Measuring perceptions of physiotherapist and other professions relative to each other (0-10). low scores indicate poor perception, high scores indicate good perception. [the minimum (8 point) and maximum values (80 point)], higher scores were mean a better outcome. | Baseline time | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge of students about the physiotherapist of health fields | In which health fields does the physiotherapist profession work. As the number increases, the level of knowledge will be determined as good, as it decreases, it will be determined as bad. [the minimum (0 point) and maximum values (24 point)], higher scores were mean a better outcome. | Baseline time |
Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The aim of this trial is to compare insulin aspart produced by current process and the NN2000 process.

Official Title
-----------------
A Single Centre, Randomized, Balanced Double Blind, Cross-Over Trial Investigating the Bioequivalence of NovoRapid® Produced by the Current Process and Insulin Aspart With the Same Formulation as NovoRapid®, Produced by the NN2000 Process

Conditions
-----------------
Diabetes, Healthy

Intervention / Treatment
-----------------
* Drug: insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Caucasian Normal findings in medical history and physical examination unless the investigator considers any abnormality to be clinically irrelevant Fasting blood glucose below or equal to 6 mmol/L Body mass index (BMI) 22.0-27.0 kg/m^2 (both inclusive) Exclusion Criteria: Participated in another clinical study with an investigational drug within the last 4 weeks Any condition requiring the regular use of any medication, including herbal remedies, over the counter medicines and vitamins. Occasional paracetamol is acceptable Known or suspected allergy to the trial product or related products Family history of type 2 diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NN2000<br> | Drug: insulin aspart<br>* Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits<br>|
| Active Comparator: IAsp<br> | Drug: insulin aspart<br>* Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the Curve (AUC) (insulin aspart) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax (maximum plasma concentration) |  |  | 
| Terminal half life (t½) |  |  | 
| Incident of hypoglycaemic episodes |  |  | 
| Adverse events |  |  |
Pallidal Stimulation in Patients With Idiopathic Generalised Dystonia

Study Overview
=================
Brief Summary
-----------------
Pallidal stimulation is effective in patients with generalised idiopathic dystonia. The aim of this study is to: evaluate the efficacy and safety of this treatment in patients with idiopathic generalised dystonia, 3 years after surgery and assess the recurrence of the motor symptoms after the switch off.

Conditions
-----------------
Dystonia

Intervention / Treatment
-----------------
* Procedure: Deep brain stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Idiopathic generalised dystonia Pallidal stimulation Exclusion Criteria: Mini-mental status (MMS) < 24 Severe psychiatric disorder

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Deep brain stimulation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Idiopathic dystonia, deep brain stimulation, globus pallidus, generalised Idiopathic dystonia
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety and efficacy of S-1 and oxaliplatin combined with radiation by Phase I/II study. The purpose of this study is as follows, In phase I, to determine the dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD). In phase II, to evaluate the antitumor effect (pCR rate) and the safety .

Official Title
-----------------
A Phase I/II Study of S-1 and Oxaliplatin Combined With Radiation for Preoperative Locally Advanced Rectal Carcinoma. (SHOGUN Trial)

Conditions
-----------------
Rectal Carcinoma

Intervention / Treatment
-----------------
* Drug: S-1
* Drug: Oxaliplatin
* Radiation: Radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with confirmed locally advanced and non-metastatic rectal adenocarcinoma (clinical stage T3, anyN or T4, anyN) Possible to R0 resection Received no prior therapy Performance status (ECOG) 0-1 Normal organ and marrow function. Sufficient oral intake Exclusion Criteria: History of serious allergic reaction Patients without serious complications such as sensory neurotoxicity or serious diarrhea (with watery stool). Female with pregnancy or lactation Have another malignancy in the past 5 years except early stage other cancer that cure by local treatment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: S-1<br>* 40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.<br>Drug: Oxaliplatin<br>* 40-60mg/m2/week intravenously on day 1, 8, 22 and 29.<br>Radiation: Radiation<br>* Total dose is 50.4Gy (1.8Gy X 28 fractions)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phase I: Determine the Recommended dose (RD) | Based on the incidence of dose-limited toxicities(DLT), the RD is determined from 4 test levels | 10 weeks | 
| Phase II: pathological complete response rate | Pathological complete response(pCR) rate is calculated by numbers of pCR cases (grade 3) devided the number of subjected cases. | 12-16 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| R0 resection rate |  | 12-16 weeks | 
| down staging rate |  | 12-16 weeks | 
| local reccurence rate |  | 3 years | 
| desease free survuval |  | 3 years | 
| safety |  | 16-20 weeks |
Living Donor Liver Transplantation in Children

Study Overview
=================
Brief Summary
-----------------
Evaluate the outcome of pediatric living donor liver transplantation (LDLT) regarding portal vein reconstruction, ABO-compatibility and impact of maternal donation on graft acceptance.

Detailed Description
-----------------
Data from 250 pediatric LDLT recipients (and their donors), transplanted at Cliniques universitaires Saint-Luc between July 1993 and June 2012, were collected retrospectively using electronic data files. Results were analysed according to ABO matching and portal vein complications. Uni- and multi-variate analysis was used to study the impact of immunosuppression, gender match and maternal donation on acute rejection rate.

Official Title
-----------------
Living Donor Liver Transplantation in Children: Surgical and Immunological Results in 250 Recipients at Université Catholique de Louvain.

Conditions
-----------------
Pediatric Liver Transplanted Recipients, Healthy Donors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children receiving a living donor liver transplant Adult living donors Exclusion Criteria: No one

Ages Eligible for Study
-----------------
Maximum Age: 57 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient and graft survival | Kaplan-Meier | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Portal vein complications |  | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver failure, liver malignancy, metabolic diseases, Pediatric liver transplanted recipients and their healthy donors
Prescribing Exercise to Cancer Patients at High-Risk for Falls

Study Overview
=================
Brief Summary
-----------------
Falls are common and catastrophic in cancer patients. Cancer patients are vulnerable to falls due to muscle loss. In prescribing exercise in a data driven manner to cancer patients, our hypothesis is this prescription for exercise will eventually be demonstrated to reduce the occurrence of injurious falls.

Official Title
-----------------
Prescribing Exercise to Cancer Patients at High-Risk for Falls

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Other: Pedometer
* Other: Actigraph
* Other: Perturbation Treadmill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any cancer diagnosis, as documented in medical record, other than non-melanoma skin cancer. No issues such as unstable angina or loss of a limb that would preclude exercise. Exclusion Criteria: Diagnosis of non-melanoma skin cancer Unstable angina Loss of limb, which limits exercise capabilities at the discretion of the Principal Investigators Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Interventional Model Description: The investigator will incrementally increase the exercise prescription for groups of patients.
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Pedometer|Participants will wear a pedometer for 4 days at baseline, and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.|
|Other: Actigraph|Participants will wear a Actigraph for 4 days at baseline and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.|
|Other: Perturbation Treadmill|Participants will walk on an instrumented treadmill while wearing a safety harness at baseline and 4-6 weeks later. The perturbation treadmill will assess an individual's risk for falling. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ABC Activities Specific Balance Confidence Scale (exploratory outcome) | Patient Reported Outcome 0% No confidence, 100% Complete Confidence, higher score= better outcome | Change from baseline ABC scale at 4-6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise, Falls
Correlative Study on Incidence and Risk Factors of Glaucoma-related Adverse Event at Various Durations After Congenital Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
A retrospective chart review of 264 eyes from 177 patients was performed who underwent congenital cataract surgery before the age of 14 years. All patients' surgery was performed by the same experienced surgeon at the Eye Hospital of Wenzhou Medical University from May 2011 to March 2019. We recorded patient demographics and incidence and risk factors for glaucoma-related adverse event. This study to identify the incidence of and risk factors associated with postoperative glaucoma at various durations after congenital cataract surgery.

Official Title
-----------------
Correlative Study on Incidence and Risk Factors of Glaucoma-related Adverse Event at Various Durations After Congenital Cataract Surgery

Conditions
-----------------
The Incidence and Risk Factors of Glaucoma After Congenital Cataract Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent lensectomy combined with limited anterior vitrectomy, with or without IOL implantation for congenital cataract, all by one surgeon Exclusion Criteria: Patient had a preoperative IOP above 21mmHg, glaucoma, coexistent uveitis, metabolic syndromes/diseases or exposure to radiation.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Group 1 includes patients who underwent cataract surgery with primary IOL implantation | |
| Group 2<br>Group 2 includes patients who underwent cataract surgery with secondly IOL implantation | |
| Group 3<br>Group 3 includes patients who underwent cataract surgery without IOL implantation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of glaucoma after congenital cataract surgery | The incidence of glaucoma at various durations after congenital cataract surgery | 2020.6.30 | 
| Demographic data, including sex, age at surgery, gestational history, family history of cataract, and laterality of disease, were collected. | Risk factors | 2020.6.30 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Incidence, Congenital cataract surgery
Sleep Disturbance in Deployed Soldiers

Study Overview
=================
Brief Summary
-----------------
Hypotheses: Hypothesis 1 - Sleep can be measured in Theater using actigraph technology. Hypothesis 2 - Standard sleep measures in Soldiers randomized to a sleep intervention group will more closely approximate normal as compared to sleep measures of Soldiers randomized to the control group.

Official Title
-----------------
Sleep Disturbance in Deployed Soldiers

Conditions
-----------------
Sleep Disturbance

Intervention / Treatment
-----------------
* Other: Relaxation CD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All study participants must be on Active Duty, or be Reserve or National Guard Service Members notified of impending deployment. Recruited prior to deployment in order to obtain baseline measures before deployment. Have been stateside at least one full year. Able to read and speak English and consent themselves. Exclusion Criteria: Subjects with self-identified sleep disorder (for example restless leg syndrome or sleep apnea) Pregnancy. Pregnant women will be excluded from the study since pregnancy places women in a non-deployable status and pregnant Soldiers will not be deploying.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Intervention Group | Other: Relaxation CD<br>* A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Actigraph and self report questionnaires |  | baseline, 6 months, 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self report questionnaires |  | baseline, 6 months, 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleep, disturbance, deployment, intervention, actigraph
Wormwood in Chronic Progressive Disorders With Reduced Appetite

Study Overview
=================
Brief Summary
-----------------
Wormwood is approved herbal medicine for the treatment of reduced appetite in Germany (Registration No.: 1339.99.99). Reduced appetite is observed in many chronic health disorders such as old age, immune disorders and cancer. Trial aims at observing beneficial effects of wormwood supplementation in various chronic disorders associated with reduced appetite

Detailed Description
-----------------
Supplementation with wormwood in chronic disorders associated with reduced appetite. Examples: Cancer Autoimmune diseases such as Crohns disease and IgA Nephropathy Old age Chronic stress and depression

Official Title
-----------------
Pilot Trial With Wormwood to Improve Appetite in Cancer, Autoimmune Diseases, Depression and Old Age

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Appetite and weight loss Chronic progressive disease Exclusion Criteria: Life expectancy less than 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in appetite |  | 6-12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in quality of life |  | 12-24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crohn disease, Involuntary weight loss in cancer, IgA nephropathy, Depression with reduced appetite